Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection

Journal of Thoracic and Cardiovascular Surgery

Volumn 145, Issue 4, 2013, Pages 955-963

  Sugarbaker, David J ^a   Gill, Ritu R ^a   Yeap, Beow Y ^b   Wolf, Andrea S ^a   Dasilva, Marcelo C ^a   Baldini, Elizabeth H ^a   Bueno, Raphael ^a   Richards, William G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; HEMOGLOBIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CYTOREDUCTIVE SURGERY; FEMALE; FISHER EXACT TEST; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC INTRAOPERATIVE CISPLATIN CHEMOTHERAPY; HYPERTHERMIC THERAPY; KAPLAN MEIER METHOD; LAVAGE; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INTRAOPERATIVE CARE; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PLEURAL NEOPLASMS; PNEUMONECTOMY; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 84875209554     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2012.12.037     Document Type: Article

References (26)

1. D.J. Sugarbaker Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma J Thorac Oncol 1 2006 175 176
2. D.J. Sugarbaker, R.M. Flores, M.T. Jaklitsch, W.G. Richards, G.M. Strauss, and J.M. Corson Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients J Thorac Cardiovasc Surg 117 1999 54 65
3. E.H. Baldini, A. Recht, G.M. Strauss, M.M. DeCamp Jr., S.J. Swanson, and M.J. Liptay Patterns of failure after trimodality therapy for malignant pleural mesothelioma Ann Thorac Surg 63 1997 334 338
4. W.G. Richards, L. Zellos, R. Bueno, M.T. Jaklitsch, P.A. Janne, and L.R. Chirieac Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma J Clin Oncol 24 2006 1561 1567
5. L. Zellos, W.G. Richards, L. Capalbo, M.T. Jaklitsch, L.R. Chirieac, and B.E. Johnson A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma J Thorac Cardiovasc Surg 137 2009 453 458
6. T.R. Tilleman, W.G. Richards, L. Zellos, B.E. Johnson, M.T. Jaklitsch, and J. Mueller Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study J Thorac Cardiovasc Surg 138 2009 405 411
7. D.J. Sugarbaker, A.S. Wolf, L.R. Chirieac, J.J. Godleski, T.R. Tilleman, and M.T. Jaklitsch Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy Eur J Cardiothorac Surg 40 2011 298 303
8. A.S. Wolf, W.G. Richards, T.R. Tilleman, L. Chirieac, S. Hurwitz, and R. Bueno Characteristics of malignant pleural mesothelioma in women Ann Thorac Surg 90 2010 949 956
9. W.D. Travis, T.V. Colby, B. Corrin, Y. Shimosato, and E. Brambilla World Health Organization international histological classification of tumours: histological typing of lung and pleural tumours 3rd ed. 1999 Springer Berlin
10. R.R. Gill, W.G. Richards, B.Y. Yeap, S. Matsuoka, A.S. Wolf, and V.H. Gerbaudo Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume AJR Am J Roentgenol 198 2012 359 363
11. R.R. Gill, B.Y. Yeap, S. Matsuoka, A.S. Wolf, R. Bueno, and H. Hatabu Stage-independent pre-operative prognostic grouping of surgically treated patients with epithelial malignant pleural mesothelioma: 14th World Conference on Lung Cancer, Amsterdam J Thorac Oncol 6 2011 S486 S487
12. V.W. Rusch A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group Chest 108 1995 1122 1128
13. W.G. Richards Recent advances in mesothelioma staging Semin Thorac Cardiovasc Surg 21 2009 105 110
14. D.J. Sugarbaker, G.M. Strauss, T.J. Lynch, W. Richards, S.J. Mentzer, and T.H. Lee Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma J Clin Oncol 11 1993 1172 1178
15. R. Bueno, J. Reblando, J. Glickman, M.T. Jaklitsch, J.M. Lukanich, and D.J. Sugarbaker Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma Ann Thorac Surg 78 2004 1774 1776
16. S.C. Kao, T.D. Yan, K. Lee, J. Burn, D.W. Henderson, and S. Klebe Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma J Thorac Oncol 6 2011 602 605
17. W.G. Richards, J.J. Godleski, B.Y. Yeap, J.M. Corson, L.R. Chirieac, and L. Zellos Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases Cancer 116 2010 1510 1517
18. A. Nakas, E. Black, J. Entwisle, S. Muller, and D.A. Waller Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage? Eur J Cardiothorac Surg 37 2010 1457 1463
19. E.H. Baldini Radiation therapy options for malignant pleural mesothelioma Semin Thorac Cardiovasc Surg 21 2009 159 163
20. T. Berghmans, M. Paesmans, Y. Lalami, I. Louviaux, S. Luce, and C. Mascaux Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis Lung Cancer 38 2002 111 121
21. V.W. Rusch, D. Niedzwiecki, Y. Tao, C. Menendez-Botet, A. Dnistrian, and D. Kelsen Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies J Clin Oncol 10 1992 1001 1006
22. R. Lerza, M. Esposito, M. Vannozzi, G.B. Bottino, G. Bogliolo, and I. Pannacciulli High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma Cancer 73 1994 79 84
23. M.J. Byrne, J.A. Davidson, A.W. Musk, J. Dewar, G. van Hazel, and M. Buck Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study J Clin Oncol 17 1999 25 30
24. N.J. Vogelzang, J.J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, and P. Ruffie Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2003 2636 2644
25. P.S. Adusumilli, M.K. Chan, Y.S. Chun, M. Hezel, T.C. Chou, and V.W. Rusch Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma Cancer Biol Ther 5 2006 48 53
26. J.R. Anderson, K.C. Cain, and R.D. Gelber Analysis of survival by tumor response J Clin Oncol 1 1983 710 719